"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

But the man’s condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver ...

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

There’s a stigma surrounding liver cancer. Once you tell people you’ve got it, often you sense a slight judgment. “Oh”, you ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...